Abivax SA (ABVX) Stock Analysis

Q: What is the ABVX stock price target?

Take-profit $135.02 (+19.7% upside). Prior stop was $104.94.

Q: Is ABVX overvalued or undervalued?

Abivax SA trades at a P/E of N/A (forward -37.3). TrendMatrix value score: 7.5/10. Overall verdict: Sell.

Q: What do analysts say about ABVX?

14 analysts cover ABVX with a consensus score of 4.3/5. Average price target: $155.

SellVALUE-TRAP 3/5Moderate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

$112.62+19.7% A.UpsideScore 4.7/10#118 of 158 Biotechnology

Stop $104.94Target $135.02(analyst − 13%)A.R:R 2.1:1

Analyst target$155.20+37.8%10 analysts

$135.02our TP

$112.62price

$155.20mean

$176

Sell if holding. Engine safety override at $112.62: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 2.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.7/10, moderate confidence.

Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 131d clear, semi cycle peak clear). Fails on weak momentum. Suitability: moderate.

Thesis

Rewards

No bull case signals

Risks

Quality below floor (2.9 < 4.0)

Value-trap signals (3/5): High leverage (D/E 4.3), Material insider selling (12 sells, 0.02% of cap), Negative free cash flow

Key Metrics

P/E (TTM)—

P/E (Fwd)-37.3

Mkt Cap$8.4B

EV/EBITDA-32.3

Profit Mgn0.0%

ROE-135.6%

Rev Growth-55.4%

Beta-0.10

DividendNone

Rating analysts14

Quality Signals

Piotroski F3/9

Options Flow

P/C0.70bullish

IV89%elevated

Max Pain$75-33.4% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

4 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value7.515%1.13

Quality2.915%0.43

Growth5.015%0.75

Momentum2.710%0.27

Sentiment7.610%0.76

Insider Activity5.010%0.50

Peer Rank1.810%0.18

Technical Setup6.05%0.30

Risk Profile4.25%0.21

Catalyst2.55%0.13

Overall (Σ contributions)4.65

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

0.0

Growth Rank

1.6

Value Rank

5.0

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History

0.0

Surprise Avg

0.0

Erm

5.0

Earnings Timing

5.0

Earnings concerns: 1B/3M

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd

0.0

Volume

0.5

Obv

1.0

Ma Position

4.0

Rsi

7.8

Uptrend pullback (RSI 37) - buy opportunityVolume distribution (falling OBV)Above 200-day MA

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Net Margin

0.0

Fcf Quality

0.0

Rule Of 40

3.0

Piotroski F

3.3

Current Ratio

5.0

Moat

5.0

Gross Margin

10.0

Cash-burning: FCF -2589% of revenueNo competitive moatRule of 40: -2644 (fail)Weak Piotroski F-Score: 3/9Quality concerns

GatesMomentum 2.7<4.5A.R:R 2.1 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 131d clearSEMI CYCLE PEAK CLEARSuitability: Moderate

RSI

37 · Neutral

↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $106.00Resistance $128.42

Price Targets

$105

$135

A.Upside+19.9%

A.R:R2.1:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (2.9 < 4.0)

! Value-trap signals (3/5): High leverage (D/E 4.3), Material insider selling (12 sells, 0.02% of cap), Negative free cash flow

! Momentum score 2.7/10 — below 4.5 minimum

Earnings

1/4 beats

Next Earnings2026-09-08 (131d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is ABVX stock a buy right now?

Sell if holding. Engine safety override at $112.62: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 2.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $104.94. Score 4.7/10, moderate confidence.

What is the ABVX stock price target?

Take-profit target: $135.02 (+19.7% upside). Prior stop was $104.94. Stop-loss: $104.94.

What are the risks of investing in ABVX?

Quality below floor (2.9 < 4.0); Value-trap signals (3/5): High leverage (D/E 4.3), Material insider selling (12 sells, 0.02% of cap), Negative free cash flow.

Is ABVX overvalued or undervalued?

Abivax SA trades at a P/E of N/A (forward -37.3). TrendMatrix value score: 7.5/10. Verdict: Sell.

What do analysts say about ABVX?

14 analysts cover ABVX with a consensus score of 4.3/5. Average price target: $155.

What does Abivax SA do?ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural...

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.